Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PPOX | P50336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188488 | 0.78 | PGR (0.40) | DRD2HTR2CHTR2AHTR2BAKT1 | |
| SCHEMBL25355455 | 0.71 | MEN1 (0.43) | PDK2 | |
| SCHEMBL25358373 | 0.67 | HTR2C (0.52) | DRD2HTR2CHTR2AHTR2BAKT1 | |
| SCHEMBL29506005 | 0.66 | F7 (0.44) | DRD2HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL22493790 | 0.66 | HTR2C (0.42) | DRD2HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL21856169 | 0.66 | F7 (0.44) | DRD2HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL13387691 | 0.65 | HTR2C (0.44) | DRD2HTR2CHTR2AHTR2BAKT1 | |
| Hydrochloric Acid SCHEMBL21855899 | 0.65 | HTR2C (0.41) | DRD2HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL1513519 | 0.64 | DRD2 (0.58) | PDK2DRD2HTR2CHTR2AHTR2B | |
| SCHEMBL12084866 | 0.64 | HTR2C (0.46) | DRD2HTR2CHTR2AHTR2BAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4476207-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, SAAL1 | PDK2 344/4885DRD2 1882/4885HTR2C 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.